COLL
Price
$38.32
Change
-$0.91 (-2.32%)
Updated
Sep 5 closing price
Capitalization
1.21B
61 days until earnings call
PCRX
Price
$26.46
Change
-$0.27 (-1.01%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
1.19B
54 days until earnings call
Interact to see
Advertisement

COLL vs PCRX

Header iconCOLL vs PCRX Comparison
Open Charts COLL vs PCRXBanner chart's image
Collegium Pharmaceutical
Price$38.32
Change-$0.91 (-2.32%)
Volume$470.06K
Capitalization1.21B
Pacira BioSciences
Price$26.46
Change-$0.27 (-1.01%)
Volume$26.04K
Capitalization1.19B
COLL vs PCRX Comparison Chart in %
Loading...
COLL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
COLL vs. PCRX commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COLL is a Hold and PCRX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (COLL: $38.32 vs. PCRX: $26.45)
Brand notoriety: COLL and PCRX are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: COLL: 127% vs. PCRX: 91%
Market capitalization -- COLL: $1.21B vs. PCRX: $1.19B
COLL [@Pharmaceuticals: Generic] is valued at $1.21B. PCRX’s [@Pharmaceuticals: Generic] market capitalization is $1.19B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.93B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

COLL’s FA Score shows that 1 FA rating(s) are green whilePCRX’s FA Score has 0 green FA rating(s).

  • COLL’s FA Score: 1 green, 4 red.
  • PCRX’s FA Score: 0 green, 5 red.
According to our system of comparison, COLL is a better buy in the long-term than PCRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

COLL’s TA Score shows that 4 TA indicator(s) are bullish while PCRX’s TA Score has 6 bullish TA indicator(s).

  • COLL’s TA Score: 4 bullish, 6 bearish.
  • PCRX’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, PCRX is a better buy in the short-term than COLL.

Price Growth

COLL (@Pharmaceuticals: Generic) experienced а -1.24% price change this week, while PCRX (@Pharmaceuticals: Generic) price change was -0.82% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.08%. For the same industry, the average monthly price growth was +12.00%, and the average quarterly price growth was +86.48%.

Reported Earning Dates

COLL is expected to report earnings on Nov 06, 2025.

PCRX is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.08% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
COLL($1.21B) and PCRX($1.19B) have the same market capitalization . COLL has higher P/E ratio than PCRX: COLL (36.15) vs PCRX (13.04). PCRX YTD gains are higher at: 41.879 vs. COLL (33.752). COLL has higher annual earnings (EBITDA): 347M vs. PCRX (-1.3M). PCRX has more cash in the bank: 446M vs. COLL (222M). PCRX has less debt than COLL: PCRX (631M) vs COLL (829M). COLL (707M) and PCRX (706M) have equivalent revenues.
COLLPCRXCOLL / PCRX
Capitalization1.21B1.19B102%
EBITDA347M-1.3M-26,672%
Gain YTD33.75241.87981%
P/E Ratio36.1513.04277%
Revenue707M706M100%
Total Cash222M446M50%
Total Debt829M631M131%
FUNDAMENTALS RATINGS
COLL vs PCRX: Fundamental Ratings
COLL
PCRX
OUTLOOK RATING
1..100
798
VALUATION
overvalued / fair valued / undervalued
1..100
68
Overvalued
57
Fair valued
PROFIT vs RISK RATING
1..100
39100
SMR RATING
1..100
5295
PRICE GROWTH RATING
1..100
4041
P/E GROWTH RATING
1..100
7100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PCRX's Valuation (57) in the Pharmaceuticals Other industry is in the same range as COLL (68). This means that PCRX’s stock grew similarly to COLL’s over the last 12 months.

COLL's Profit vs Risk Rating (39) in the Pharmaceuticals Other industry is somewhat better than the same rating for PCRX (100). This means that COLL’s stock grew somewhat faster than PCRX’s over the last 12 months.

COLL's SMR Rating (52) in the Pharmaceuticals Other industry is somewhat better than the same rating for PCRX (95). This means that COLL’s stock grew somewhat faster than PCRX’s over the last 12 months.

COLL's Price Growth Rating (40) in the Pharmaceuticals Other industry is in the same range as PCRX (41). This means that COLL’s stock grew similarly to PCRX’s over the last 12 months.

COLL's P/E Growth Rating (7) in the Pharmaceuticals Other industry is significantly better than the same rating for PCRX (100). This means that COLL’s stock grew significantly faster than PCRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
COLLPCRX
RSI
ODDS (%)
Bearish Trend 1 day ago
69%
Bearish Trend 2 days ago
74%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
65%
Bearish Trend 2 days ago
79%
Momentum
ODDS (%)
Bearish Trend 1 day ago
71%
Bullish Trend 3 days ago
74%
MACD
ODDS (%)
Bearish Trend 1 day ago
62%
Bullish Trend 3 days ago
68%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
65%
Bullish Trend 2 days ago
66%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
72%
Bullish Trend 2 days ago
69%
Advances
ODDS (%)
Bullish Trend 3 days ago
71%
Bullish Trend 9 days ago
69%
Declines
ODDS (%)
Bearish Trend 1 day ago
64%
Bearish Trend 2 days ago
78%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
64%
Bearish Trend 2 days ago
78%
Aroon
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 2 days ago
69%
View a ticker or compare two or three
Interact to see
Advertisement
COLL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
OPPAX102.130.26
+0.26%
Invesco Global A
TGCNX25.550.01
+0.04%
TCW Concentrated Large Cap Growth N Cl
GCEDX9.78N/A
N/A
Goldman Sachs Clean Energy Income Ins
FSUTX128.73N/A
N/A
Fidelity Select Utilities
FLSPX14.88N/A
N/A
Meeder Spectrum Retail

COLL and

Correlation & Price change

A.I.dvisor indicates that over the last year, COLL has been loosely correlated with AMPH. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if COLL jumps, then AMPH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To COLL
1D Price
Change %
COLL100%
-2.32%
AMPH - COLL
41%
Loosely correlated
+0.79%
AMRX - COLL
39%
Loosely correlated
+0.73%
VTRS - COLL
37%
Loosely correlated
+1.65%
ALKS - COLL
36%
Loosely correlated
+3.53%
ANIP - COLL
33%
Loosely correlated
-0.68%
More

PCRX and

Correlation & Price change

A.I.dvisor tells us that PCRX and ALKS have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PCRX and ALKS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PCRX
1D Price
Change %
PCRX100%
-1.66%
ALKS - PCRX
33%
Poorly correlated
-3.60%
ELAN - PCRX
31%
Poorly correlated
+0.69%
COLL - PCRX
29%
Poorly correlated
-0.91%
TEVA - PCRX
29%
Poorly correlated
-1.49%
ETON - PCRX
29%
Poorly correlated
+2.41%
More